Market closedNon-fractional

Monte Rosa Therapeutics/GLUE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Monte Rosa Therapeutics

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Ticker

GLUE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boston, United States

Employees

130

GLUE Metrics

BasicAdvanced
$223M
Market cap
-
P/E ratio
-$2.50
EPS
1.54
Beta
-
Dividend rate
$223M
1.54
4.82
4.686
27.431
29.624
-31.26%
-68.28%
185.082
1.2
1.2
-2.821
2.75%
-55.07%

What the Analysts think about GLUE

Analyst Ratings

Majority rating from 8 analysts.
Buy

GLUE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-3,190.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
∞%
Net income
-$32M
-3.92%
Profit margin
-3,190.00%
-∞%

GLUE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.48%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.71
-$0.70
-$0.58
-$0.53
-
Expected
-$0.70
-$0.72
-$0.33
-$0.57
-$0.54
Surprise
1.43%
-3.28%
73.28%
-7.48%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Monte Rosa Therapeutics stock?

Monte Rosa Therapeutics (GLUE) has a market cap of $223M as of July 06, 2024.

What is the P/E ratio for Monte Rosa Therapeutics stock?

The price to earnings (P/E) ratio for Monte Rosa Therapeutics (GLUE) stock is 0 as of July 06, 2024.

Does Monte Rosa Therapeutics stock pay dividends?

No, Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Monte Rosa Therapeutics dividend payment date?

Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders.

What is the beta indicator for Monte Rosa Therapeutics?

Monte Rosa Therapeutics (GLUE) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Monte Rosa Therapeutics stock

Buy or sell Monte Rosa Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing